What is the recommended dosing regimen for BIXLENVO (bictegravir/lenacapavir)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

BIXLENVO Dosing

BIXLENVO (bictegravir/lenacapavir) is dosed as a single tablet containing 75 mg bictegravir and 50 mg lenacapavir taken once daily orally for HIV treatment in virologically suppressed individuals. This represents a distinct dosing regimen from lenacapavir monotherapy used for PrEP, which requires subcutaneous injections.

Standard Dosing Regimen

For HIV Treatment (BIXLENVO):

  • One tablet (75 mg bictegravir/50 mg lenacapavir) once daily by mouth 1, 2
  • No loading doses required when switching from suppressive regimens
  • Can be taken with or without food

Clinical Context and Indications

BIXLENVO is specifically indicated for:

  • Virologically suppressed adults with HIV-1 (HIV-1 RNA <50 copies/mL for ≥6 months) 1, 2
  • Switching from complex multi-tablet regimens to simplify therapy 1
  • Switching from bictegravir/emtricitabine/tenofovir alafenamide in stable patients 2

Eligibility Requirements

  • No known integrase strand-transfer inhibitor (INSTI) resistance 3
  • Stable virological suppression on current regimen
  • Weight ≥35 kg (based on lenacapavir component data) 4

Important Distinctions: BIXLENVO vs Lenacapavir PrEP

Do not confuse BIXLENVO dosing with lenacapavir PrEP dosing. These are completely different regimens:

Lenacapavir for PrEP (NOT BIXLENVO):

  • Loading: Day 1: 927 mg subcutaneous injection + 600 mg oral; Day 2: 600 mg oral 4
  • Maintenance: 927 mg subcutaneous injection every 6 months 4
  • Used for HIV prevention, not treatment

BIXLENVO for HIV Treatment:

  • Once-daily oral tablet only - no injections
  • No loading doses
  • Continuous daily dosing

Efficacy Data

The combination demonstrates robust efficacy in maintaining viral suppression:

  • Week 48 data: 1.3% with HIV-1 RNA ≥50 copies/mL in the BIXLENVO group vs 1.0% in comparator groups 2
  • Week 96 extension data: All 119 participants maintained virological suppression with no treatment-emergent resistance 3
  • Effective even in patients with extensive baseline resistance to other drug classes (82% had NRTI RAMs, 66% had NNRTI RAMs) 3

Drug Interactions

Critical CYP3A considerations 5:

  • Strong CYP3A inducers (rifampin, efavirenz): Significantly reduce lenacapavir exposure (84% reduction with rifampin) - avoid or use alternative regimens
  • Strong CYP3A inhibitors (atazanavir/cobicistat): Increase lenacapavir exposure 4-6 fold - dose adjustment may be needed
  • Lenacapavir is a moderate CYP3A inhibitor: Increases midazolam exposure 3-4 fold; monitor for increased effects of CYP3A substrates

Specific Drug Interactions:

  • Rosuvastatin: 31% increase in AUC - consider dose reduction 5
  • Tenofovir: 47% increase in exposure when combined with lenacapavir 5
  • P-gp substrates: May have increased exposure

Special Populations

Renal impairment: No dose adjustment needed for severe renal impairment (CrCl 15-29 mL/min); lenacapavir is >98.5% protein-bound, so dialysis unlikely to affect levels 5

Hepatic impairment: No dose adjustment for moderate hepatic impairment (Child-Pugh B); insufficient data for severe impairment (Child-Pugh C) 5

Pregnancy: Insufficient data for BIXLENVO use in pregnancy. Current HIV treatment guidelines recommend dolutegravir-based regimens as preferred during pregnancy 6. If pregnancy occurs on BIXLENVO, consider switching to a recommended pregnancy regimen.

Common Pitfalls to Avoid

  1. Do not confuse with lenacapavir PrEP dosing - BIXLENVO is oral daily therapy only, no injections
  2. Do not use in treatment-naive patients - only studied in virologically suppressed individuals
  3. Screen for INSTI resistance before switching - not appropriate for patients with documented integrase resistance
  4. Check for strong CYP3A inducers - rifampin and similar drugs contraindicate this regimen
  5. Do not use for hepatitis B co-infection - lacks tenofovir component needed for HBV treatment; ensure HBV screening before discontinuing tenofovir-containing regimens 4

Monitoring

  • HIV-1 RNA at weeks 12,24, and 48, then every 3-6 months
  • CD4 counts remain stable (median change -16 to +42 cells/µL at week 24) 7
  • Standard HIV care monitoring (STI screening, metabolic parameters)
  • No specific laboratory monitoring required for lenacapavir component

Safety Profile

Adverse events: Similar rates between BIXLENVO and comparator regimens 1, 2

  • Drug-related adverse events: 10% vs 12% in control groups
  • Serious adverse events: 7% in both groups
  • Discontinuation due to adverse events: 2% with BIXLENVO vs 1% with complex regimens 1

Treatment satisfaction: Participants reported increased satisfaction after switching to BIXLENVO from complex regimens 1

References

Related Questions

For an adult with HIV who is virologically suppressed on Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) after recent jaw lymphoma excision, should I continue Biktarvy and discontinue Pifeltro (doravirine)?
In which clinical situations is kyphoplasty most effective?
What are the guideline recommendations for holding systemic anticoagulation before a colonoscopy with potential polypectomy?
What is the best medication for urinary incontinence?
With an HDL cholesterol of 64 mg/dL and LDL cholesterol of 117 mg/dL, how should I manage my lipid profile?
When is Tamiflu (oseltamivir) treatment recommended?
What are the differences in emergency department management between posterior vitreous detachment and vitreous hemorrhage?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.